Compare MasterCard Inc (MA) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs TransMedics Group Inc — how do they compare? MasterCard Inc trades at $538.31 (market cap $483.71B), while TransMedics Group Inc trades at $74.78 (market cap $2.54B). The key difference: MasterCard Inc is far larger — about 190.4× TransMedics Group Inc's market cap, and MasterCard Inc pays a 0.64% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MA | TMDX | |
|---|---|---|
Market Cap | $483.71B | $2.54B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $598.96 | $150.42 |
52-Week Low | $471.55 | $61.99 |
Enterprise Value | $494.45B | $2.94B |
Dividend Yield | 0.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $541.66, down 0.36% on the day, with a bullish technical outlook and strong institutional interest. The stock exhibits robust fundamentals with revenue growth from $32.79B in 2025 to $33.9B projected for 2026, net income margins above 45%, and consistent earnings beats. Recent news highlights AI integration in ASEAN and initiatives to expand digital payment access, reinforcing its market leadership.
The outlook remains positive with a consensus price target of $634.27 implying 17% upside, supported by 79% analyst buy ratings. Key risks include payment disruption from stablecoins and competitive pressures, but Mastercard's innovation and profitability provide a solid foundation for long-term growth.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
